EXACT Sciences Corp. (EXAS)

68.82
0.51 0.74
NASDAQ : Health Technology
Prev Close 69.33
Open 70.19
Day Low/High 67.86 / 70.19
52 Wk Low/High 33.44 / 71.60
Volume 2.03M
Avg Volume 2.17M
Exchange NASDAQ
Shares Outstanding 121.90M
Market Cap 8.50B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Exact Sciences To Participate In June Investor Conferences

Exact Sciences To Participate In June Investor Conferences

MADISON, Wis., June 1, 2018 /PRNewswire/ -- Exact Sciences Corp.

Vince Lombardi Cancer Foundation And Exact Sciences Team Up To Fight Colon Cancer

Cologuard named official colon cancer screening partner; VLCF continues national expansion

Mark Stenhouse To Join Exact Sciences As President, Cologuard

Mark Stenhouse To Join Exact Sciences As President, Cologuard

After leading HUMIRA sales and marketing to create a blockbuster drug, Abbott Laboratories/AbbVie executive to join Cologuard team

Harry Connick, Jr. And Wife And Cancer Survivor Jill Connick Team Up To Urge People 50 And Older To Get Screened For Colon Cancer

Harry Connick, Jr. And Wife And Cancer Survivor Jill Connick Team Up To Urge People 50 And Older To Get Screened For Colon Cancer

Colon Cancer is Second Leading Cause of Cancer Deaths but Highly Treatable when Caught in Early Stages

Nobody Likes Tariffs: Cramer's 'Mad Money' Recap (Thursday 3/1/18)

Nobody Likes Tariffs: Cramer's 'Mad Money' Recap (Thursday 3/1/18)

Nobody likes tariffs, says Jim Cramer. But Trump said he'd do it. Even so, trade and tariff fears have hit Wall Street -- and investors -- hard.

Jerry Kelly Issues Cologuard Challenge, Urging Fellow PGA TOUR Champions Players To Get Screened For Colon Cancer

Jerry Kelly Issues Cologuard Challenge, Urging Fellow PGA TOUR Champions Players To Get Screened For Colon Cancer

Tournament Defending Champion and Colon Cancer Survivor Tom Lehman First to Sign Colon Cancer Awareness Pledge

Tucson Conquistadores And Cologuard Present Check To Vince Lombardi Cancer Foundation

Tucson Conquistadores And Cologuard Present Check To Vince Lombardi Cancer Foundation

MVP quarterback Aaron Rodgers joins announcement at Cologuard Classic

More Than 1 Million Screened For Colorectal Cancer With Cologuard

More Than 1 Million Screened For Colorectal Cancer With Cologuard

Noninvasive test is changing how Americans get checked for the most preventable form of cancer

Notable Friday Option Activity: EXAS, GTLS, CARB

Notable Friday Option Activity: EXAS, GTLS, CARB

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in EXACT Sciences Corp. , where a total volume of 12,345 contracts has been traded thus far today, a contract volume which is representative of approximately 1.2 million underlying shares (given that every 1 contract represents 100 underlying shares).

EXACT Sciences Corp. Larger Than S&P 500 Component Tripadvisor

EXACT Sciences Corp. Larger Than S&P 500 Component Tripadvisor

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component EXACT Sciences Corp. was identified as having a larger market cap than the smaller end of the S&P 500, for example Tripadvisor Inc , according to The Online Investor.

EXACT Sciences: Wait For a Better Buying Opportunity

EXACT Sciences: Wait For a Better Buying Opportunity

The stock still looks vulnerable to further declines from a technical perspective.

Exact Sciences: Cramer's Top Takeaways

Exact Sciences: Cramer's Top Takeaways

Kevin Conroy, chairman and CEO of Exact Sciences, tells Jim Cramer about his company's expansion plans for cancer screening tests.

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

Good News Matters in This Market: Cramer's 'Mad Money' Recap (Monday 1/8/18)

From global growth and bonds to index funds, Jim Cramer explains why stocks keep going up, giving the Dow and Nasdaq their best start to the new year since 2006.

Exact Sciences To Report $265.5-266.5 Million In Revenue, 168 Percent Growth For 2017

Exact Sciences To Report $265.5-266.5 Million In Revenue, 168 Percent Growth For 2017

- Preliminary 2017 revenue between $265.5 million and $266.5 million, a year-over-year increase of 168 percent

Exact Sciences, Cognizant Technology, MetLife: 'Mad Money' Lightning Round

Exact Sciences, Cognizant Technology, MetLife: 'Mad Money' Lightning Round

Jim Cramer is bullish on Exact Sciences, Cognizant Technology, MetLife, JPMorgan Chase and more.

Sentiment Is Everything Right Now: Cramer's 'Mad Money' Recap (Thursday 11/2/17)

Sentiment Is Everything Right Now: Cramer's 'Mad Money' Recap (Thursday 11/2/17)

Sentiment is critical to the next market move, says Jim Cramer. A little negativity is great news for the bulls.

Noteworthy Monday Option Activity: EXAS, SHAK, ETM

Noteworthy Monday Option Activity: EXAS, SHAK, ETM

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in EXACT Sciences Corp. , where a total volume of 9,758 contracts has been traded thus far today, a contract volume which is representative of approximately 975,800 underlying shares (given that every 1 contract represents 100 underlying shares).

Short Interest Drops 32.5% For EXAS

Short Interest Drops 32.5% For EXAS

The most recent short interest data has been released for the 09/29/2017 settlement date, which shows a 5,295,292 share decrease in total short interest for EXACT Sciences Corp. , to 10,994,802, a decrease of 32.51% since 09/15/2017.

Short Seller's Critique of Shopify Is 'All Smoke and No Fire'

Short Seller's Critique of Shopify Is 'All Smoke and No Fire'

Analysts, consultants and Shopify users came to the company's defense when TheStreet reached out to them.

Short Interest Declines 11.3% For EXAS

Short Interest Declines 11.3% For EXAS

The most recent short interest data has been released for the 09/15/2017 settlement date, which shows a 2,075,458 share decrease in total short interest for EXACT Sciences Corp. , to 16,290,094, a decrease of 11.30% since 08/31/2017.

Short Interest Falls 11.2% For EXAS

Short Interest Falls 11.2% For EXAS

The most recent short interest data has been released for the 07/31/2017 settlement date, which shows a 2,304,856 share decrease in total short interest for EXACT Sciences Corp. , to 18,237,019, a decrease of 11.22% since 07/14/2017.

Exact Sciences' Estimates Raised on Increased Contracts With Healthcare Providers

Exact Sciences' Estimates Raised on Increased Contracts With Healthcare Providers

Venture Capital firm Benchmark reiterated its 'Buy' rating on the stock and $50 price target.

TheStreet Quant Rating: D (Sell)